The promise of gene therapies and gene-editing drugs is a long-lasting treatment thats potentially a cure. But making permanent genetic changes means any accompanying problems could be long-lasting as well, says Omega Therapeutics CEO Mahesh Karande.
Omega is developing technology that takes a more nuanced approach to genomic medicine. Instead of fixing or replacing faulty genes, the company aims to harness the biological system that regulates them. If a gene is not properly translating DNA instructions into a needed protein, Omega can tune the gene expression up, Karande says. If gene expression is too high, the companys technology dials it down.
We have basically tapped into the control room of biology, says Karande, a former executive at Macrolide Pharmaceuticals and Novartis (NYSE: NVS). Our therapeutics are allowing genes to express at their native, correct level of expression. We tap into that biology.
Now the Cambridge, MA-based biotech has tapped into something more: $85 million in financing. Karande says the cash will support multiple programs, the first of which is expected to reach clinical testing in 2021.
The system that regulates genes is called the epigenome. The targets of Omegas drugs are insulated genomic domains (IGDs), three-dimensional structures that rise up from the folds of DNA. IGDs regulate the activity of a gene, similar to the way a thermostat regulates the temperature of a room, the company says. Omega has developed technology that identifies IDGs and their biological functions in states of both health and disease.
Omegas drugs are fusion proteins made up of a delivery system that takes the therapy to specific cell types, a targeting domain that binds to a specific site on the IGD, and a functional domain engineered to tweak the activity level of the IGD as needed. A single Omega drug can control the gene expression of a single gene or multiple genes, Karande says. The company can also control the length of time that a drug works, making it last days, weeks, or longer. That makes the treatment applicable for acute conditions of short duration. And unlike the permanent change made by genomic medicines, if an epigenomic Omega therapy is no longer needed, it can be turned off.
Most gene therapies and gene-editing drugs are delivered by engineered viruses. In addition to hitting the intended genetic target, these viruses can also hit other places, causing side effects, says Tom McCauley, Omegas chief scientific officer. Also, gene-editing drugs use cutting enzymes that can snip unintended spots along the genome, sparking off-target effects. By contrast, Omegas targeted approach gives its drugs the potential to more safely treat genomic disorders with a degree of control not offered by gene therapies or gene-editing drugs, McCauley says.
There are other epigenetic medicines companies. Cambridge, MA-based Epizyme (NASDAQ: EPZM) is developing drugs addressing the genetic causes of disease. In January, the FDA approved the companys small molecule drug tazemetostat (Tazverik) as a treatment for the rare cancer epithelioid sarcoma. In June, it won an an additional nod for follicular lymphoma. The most advanced drug candidate, developed by another Cambridge-based epigenetics biotech, Constellation Pharmaceuticals (NASDAQ: CNST), is a small molecule in mid-stage testing in myelofibrosis, a rare blood cancer.
Theres a reason that most of the epigenetic medicines currently available and in drug pipelines are small molecules addressing some form of cancer, McCauley says. Those drugs do hit their cancer targets but they also go elsewhere in the body, sparking side effects, he says. That risk is acceptable in rare cancers, but untenable for other diseases. Cancer is one of Omegas disease targets, but McCauley says that Omegas capability to modulate the epigenome could more safely and effectively address other diseases as well.
The IDG science that is the basis for Omegas epigenomic approach stems from the research of Richard Young and Rudolf Jaenisch, MIT biology professors and members of the Whitehead Institute for Biomedical Research. In 2016, their research was published in the journal Cell. They are both scientific advisors to Omega, which was founded in 2017 by venture capital firm Flagship Pioneering, the companys only disclosed financial backer. The firm has a track record of starting companies, incubating them, and then spinning them out to advance their research.
Omega emerged from stealth last September. Karande would not say much about the companys disease targets then, and hes saying only a little more now. Without naming specific conditions, Karande says his startup aims to treat inflammatory and immunological disorders, metabolic conditions, and rare diseases where a targeted approach to modulating the epigenome enables the company to hit disease targets previously considered undruggable. The company currently has five programs. Karande says the new financing is enough to support all five, though he leaves open the possibility that some of them could be advanced in partnership with a large pharmaceutical company.
Were on a journey right now to get five programs, in a staggered fashion, into the clinic, he says. As we make milestones in the next few months, we will be talking about them.
Frank Vinluan is an Xconomy editor based in Research Triangle Park. You can reach him at firstname.lastname@example.org.
Read the original:
- Reducing barriers to mainstream gene therapy - BioPharma-Reporter.com - September 4th, 2020
- Mapping Genetic Diversity of Lung Tumors Over Time May Lead to More Effective Therapies - UCSF News Services - September 4th, 2020
- Multi-site study to evaluate the role of testing guidelines in ensuring access to genetic information for men with prostate cancer - PRNewswire - September 4th, 2020
- Global Prime Editing Market to Witness Heightened Growth During the Period 2020 2030 - The Daily Chronicle - September 4th, 2020
- Liquid biopsies to disrupt the oncology testing market - Medical Device Network - September 4th, 2020
- Global RNA-interference (RNAi) Market Growth, Trends and Forecasts to 2025: Focus on Key Players Alnylam Pharmaceuticals, Arrowhead, Quark... - September 4th, 2020
- Yale researchers find a cause and possible treatment for Fragile X - Yale News - September 4th, 2020
- 'Coming into their own': FDA approval of liquid biopsy tests puts early, less invasive cancer detection in broader reach - USA TODAY - September 4th, 2020
- Fusion Genes Associated With More Aggressive Papillary Thyroid Cancer in Pediatric Patients - Targeted Oncology - September 4th, 2020
- Existing Class of Drugs May Improve Neurological Function in Patients with Rare, Aggressive Genetic Disorder - Newswise - September 4th, 2020
- Genomic analysis reveals insights on virulent, emerging foodborne pathogen - UB Now: News and views for UB faculty and staff - University at Buffalo... - September 4th, 2020
- Hyperthyroidism is associated with breast cancer risk and mammographic and genetic risk predictors - 2 Minute Medicine - September 4th, 2020
- Health history platform launches to trace genetic conditions | Digital Healthcare - Healthcare Global - Healthcare News, Magazine and Website - September 4th, 2020
- New HIV Gene Therapy, CAR-T Treatments Could be on the Horizon for Patients - BioSpace - September 4th, 2020
- Cell Suicide Gene Further Linked to Immunotherapy Response - Technology Networks - September 2nd, 2020
- Genetic mutations may be linked to infertility, early menopause - Washington University School of Medicine in St. Louis - September 2nd, 2020
- How to use precision medicine to personalise COVID-19 treatment according to the patient's genes - Down To Earth Magazine - September 2nd, 2020
- UCT professors research offers hope of treatment for sickle cell anaemia - Daily Maverick - September 2nd, 2020
- Association of recent stressful life events with mental and physical health in the context of genomic and exposomic liability for schizophrenia - 2... - September 2nd, 2020
- Finding order in the chaos of cancer mutations - Drug Target Review - September 2nd, 2020
- Mustang Bio Announces Orphan Drug Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency in Newly Diagnosed Infants -... - September 2nd, 2020
- Novavax Announces Publication of Phase 1 Data for COVID-19 Vaccine Candidate in The New England Journal of Medicine - GlobeNewswire - September 2nd, 2020
- Department of Genetic Medicine | Johns Hopkins Medicine - August 10th, 2020
- Genetic Medicine | Internal Medicine | Michigan Medicine ... - August 10th, 2020
- Genetic Medicine | Department of Medicine - August 10th, 2020
- Genomics and Medicine - Genome.gov - August 10th, 2020
- New Approach to Treating Osteoarthritis Advances | NYU Langone News - NYU Langone Health - August 10th, 2020
- Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates - Business Wire - August 10th, 2020
- Here's Why Shares of Editas Medicine and Beam Therapeutics Are Soaring Today - Motley Fool - August 10th, 2020
- Grant will fund study into COVID outcome disparities in NYC - Cornell Chronicle - August 10th, 2020
- A versatile genetic control system in mammalian cells and mice responsive to clinically licensed sodium ferulate - Science Advances - August 10th, 2020
- Spark Therapeutics Deepens Drug Development Expertise in Hematology and Rare Disease with Appointment of Gallia G. Levy, MD, Ph.D., as Chief Medical... - August 10th, 2020
- Chromosomal Rearrangements Associated with Chemotherapeutic Drug Resistance | McDonnell Boehnen Hulbert & Berghoff LLP - JD Supra - August 10th, 2020
- Jae Jung, Ph.D., Appointed as Chair of Cleveland Clinic Lerner Research Institute's Department of Cancer Biology - Health Essentials from Cleveland... - August 10th, 2020
- The UK and TCELS to jointly support COVID-19 research in Thailand - GOV.UK - August 10th, 2020
- Akouos Announces Expansion of Executive Team and Board of Directors - BioSpace - August 10th, 2020
- Medical and neurobehavioural phenotypes in male and female carriers of Xp22.31 duplications in the UK Biobank. - Physician's Weekly - August 10th, 2020
- Coronavirus vaccine breakthrough: New generation cure that stops virus developed - Express - August 10th, 2020
- Global Cell and Gene Therapy Market, Forecast to 2025 by Product, Disease, End-user and Region - COVID-19 Updated - PRNewswire - August 10th, 2020
- Not Everyone Needs 8 Hours of Sleep, New Research Reveals | Time - TIME - August 10th, 2020
- Lindsey Criswell Named Director of National Institute of Arthritis and Musculoskeletal and Skin Diseases - UCSF News Services - August 10th, 2020
- Pinpointing The Cells That Keep The Bodys Master Circadian Clock Ticking - Newswise - August 10th, 2020
- Kazia Therapeutics hits A$1 on grant of Rare Pediatric Disease Designation to paxalisib for DIPG - Proactive Investors USA & Canada - August 10th, 2020
- Treatment Considerations for Prostate Cancer Progressing After Combination Therapy for mCSPC - UroToday - August 10th, 2020
- Edited Transcript of PSNL.OQ earnings conference call or presentation 6-Aug-20 9:00pm GMT - Yahoo Finance - August 10th, 2020
- Ovid and Angelini partner on treating Angelman syndrome in Europe - Pharmaceutical Technology - August 10th, 2020
- Doctoral Student/Research Assistant in Mitochondrial Biology and Signalling job with UNIVERSITY OF HELSINKI | 218596 - Times Higher Education (THE) - August 10th, 2020
- Simpler COVID-19 test could provide results in hours from saliva - University of Wisconsin-Madison - August 10th, 2020
- This company has a better version of a simpler, faster Covid-19 test - STAT - August 7th, 2020
- Mental Notes: Music Cognition Lab is dedicated to the scientific study of how music affects the brain and behavior - Vanderbilt University News - August 6th, 2020
- Nasha Fitter Elected to Board of Directors of the ACMG Foundation for Genetic and Genomic Medicine - PRNewswire - August 5th, 2020
- HDAC6 Can Control Tumor Growth and Halt Metastasis in Triple-Negative Breast Cancer - Newswise - August 5th, 2020
- Will programming a cell ever be as easy as programming an app? - SynBioBeta - August 5th, 2020
- Penn Researchers Identify New Genetic Cause of a Form of Inherited Neuropathy - Newswise - August 5th, 2020
- Genetic Variant in Persons of African Descent Linked with Stroke: Analysis - DocWire News - August 5th, 2020
- Invitae Reports $46.2 Million in Revenue Driven by More Than 120000 Samples Accessioned in the Second Quarter of 2020 - Monterey County Weekly - August 5th, 2020
- Noel R. Rose, widely regarded as the father of autoimmune disease research, dies at 92 - The Hub at Johns Hopkins - August 5th, 2020
- Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis - GlobeNewswire - August 5th, 2020
- Seragon Announces GenomeScore, the First AI Platform to Measure Rate of Aging and Physiological Changes - PRNewswire - August 5th, 2020
- Vaccine 'durability': COVID-19 immunizations coming soon but will they last? - Genetic Literacy Project - August 5th, 2020
- Aerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for the Prevention and Treatment of... - August 5th, 2020
- Stoke Therapeutics to Present at Upcoming Investor Conferences in August - Business Wire - August 4th, 2020
- The global cell and gene therapy market by revenue is expected to grow at a CAGR of over 30.90% during the period 20192025 - GlobeNewswire - August 4th, 2020
- Cochlear implant uses LEDs to tackle hearing loss - Optics.org - August 4th, 2020
- Rozlytrek, Roche's first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with... - August 4th, 2020
- Alnylam Pharmaceuticals : Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis -... - August 4th, 2020
- 'The younger the child, the likelier to find causative gene of infant epilepsy' - Korea Biomedical Review - Korea Biomedical Review - August 3rd, 2020
- Known genes associated with male infertility doubled - BioNews - August 3rd, 2020
- Alnylam Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis (NASH) - Business... - August 3rd, 2020
- Cancer drug is first therapy to emerge from 23andMe-GSK deal - STAT - STAT - August 3rd, 2020
- Dr. Rana on the Rationale for Video Genetic Counseling in Prostate Cancer - OncLive - August 3rd, 2020
- Metastatic Lung Cancer Study Finds That Bionano's Saphyr Outperforms NGS for the Detection of Structural Variants - GlobeNewswire - August 3rd, 2020
- Health Media in the COVID-19 Era: A mid-wave report - Features - MM&M - Medical Marketing and Media - August 3rd, 2020
- Cyberpunk 2077 shows off the ruined dreams district of Pacifica in new concept art - Critical Hit - August 2nd, 2020
- An unsupported American conspiracy theory found a foothold in Europe. New research shows how - NewsDio - August 2nd, 2020
- Study Suggests New Approach to Improve Radiation Therapy Resistance in Glioblastoma - Michigan Medicine - August 1st, 2020
- Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis - BioSpace - August 1st, 2020
- Our Genes May Explain Severity of COVID-19 and Other Infections - Quanta Magazine - August 1st, 2020
- EarlyBird Study: Early Detection of Adult-Onset Type 2 Diabetes in Youth - Diabetes In Control - August 1st, 2020
- Movers & Shakers, July 24 | BioSpace - BioSpace - July 31st, 2020